Abstracts tagged "pain"

Abstract Number: 2101 • ACR Convergence 2025
LEVI-04, a Novel Neurotrophin-3 Inhibitor, Demonstrates Clinically Meaningful Improvements in Pain and Physical Function across a Range of OA Outcomes, Including the Staircase-Evoked Pain Procedure (StEPP)
Philip Conaghan¹, nathaniel katz², Asger Bihlet³, Laus W Wullum⁴, Kerry af Forselles⁵, C Michael Perkins⁵, Bernadette Hughes⁶, Claire Herholdt⁷ and Iwona Bombelka⁸, ¹University of Leeds, Leeds, United Kingdom, ²Rin Sof Innovation, Ltd, Boston, MA, ³NBCD A/S, Herlev, Denmark, ⁴Omicron A/S, Copenhagen, Denmark, ⁵Levicept, Sandwich, United Kingdom, ⁶Levicept, Ashtead, United Kingdom, ⁷Levicept Ltd, Ashtead, United Kingdom, ⁸Levicept, Sandwich, Kent, United Kingdom
Background/Purpose: When evaluating new osteoarthritis (OA) therapies, we need to understand their clinical meaningfulness. LEVI-04, a first-in-class p75 neurotrophin receptor-Fc fusion protein that primarily inhibits…
Abstract Number: 1780 • ACR Convergence 2025
Modeling Osteoarthritis Knee Joint in a Compartmentalized Microfluidic System using IPSC-derived Sensory Neurons and human Synovial Fibroblasts
Abdelhak Belmadani¹, Dongjun Ren¹, Daniel Hoffman², Nirupa Jayraj¹, Paola Pacifico¹, Vince Truong³, Patrick Walsh³, Daniela Menichella¹, Anna Rapp⁴, Carla Scanzello⁵, Rachel Miller⁶, Richard Miller⁷ and Anne-Marie Malfait⁸, ¹Northwestern University Chicago, Chicago, IL, ²Rush University, Chicago, IL, ³Anatomic Inc, Minneapolis, MN, ⁴University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, ⁶Rush University Medical Center, Chicago, IL, ⁷Northwestern University, Chicago, ⁸Rush University Medical Center, Chicago
Background/Purpose: Joint pain is one of the most significant clinical hallmarks of knee osteoarthritis (OA). Knee OA is a chronic degenerative disease of the joints…
Abstract Number: 1257 • ACR Convergence 2025
Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Puneet Bajaj², Urooj Wahid², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Rheumatic diseases (RD) often cause pain, fatigue and disability. Depression and anxiety are prevalent comorbidities in RD and ideally managed with behavioral health (BH)…
Abstract Number: 1230 • ACR Convergence 2025
Chronic pain phenotypes in older adults: Identifying patterns of musculoskeletal pain and associated burden
Gillian Fennell¹, Sarah Tilley², Sayali Dhamne³, Robert Edwards⁴, Mary Gheller³, Angelo Demalia³, Margaret Clancy³, Michael LaValley⁵, Emelia J Benjamin³ and Tuhina Neogi⁶, ¹Boston University Medical, Boston, MA, ²Boston University School of Medicine, Somerville, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Brigham and Women's Hospital & Harvard Medical School, Boston, MA, ⁵Boston University School of Public Health, Arlington, MA, ⁶Boston University School of Medicine, Boston, MA
Background/Purpose: Over a third of older Americans experience chronic pain, typically occupying multiple musculoskeletal body sites. While number of pain sites (NPS) is often touted…
Abstract Number: 0817 • ACR Convergence 2025
More than 40% of Older Adults with Rheumatic Diseases Are Prescribed Opioid Medications
Christine Anastasiou¹, Eric Roberts², gabriela Schmajuk³ and Jinoos Yazdany⁴, ¹Stanford University, Pleasanton, CA, ²University of California, San Francisco, SF, CA, ³University of California, San Francisco, and San Francisco Veterans Affairs Medical Center, San Francisco, CA, ⁴UCSF, San Francisco, CA
Background/Purpose: Patients with rheumatic diseases commonly experience acute or chronic pain that may lead to both short- and long-term opioid use. Many patients do not…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: 2098 • ACR Convergence 2025
Responder Phenotype Analysis for Intra-Articular Injections: Secondary Analysis from a Large Multi-Site Crossover Clinical Trial
Natalie Keller¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁶, Criswell Lavery⁸, Bibiana Ateh⁹, Bridget Kramer², Kimberly Hayes⁶, Rui Xiao⁸, Kaitian Jin⁸, Alexis Ogdie⁸, Daniel K. White¹⁰, Tuhina Neogi¹¹, Carla Scanzello¹² and Joshua Baker⁸, ¹University of Oklahoma, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Howard University Hospital and Washington DC Veterans Affairs Medical Center, Washington, District of Columbia, ⁵Brown University, Philadelphia, PA, ⁶Corporal Michael J. Crescenz VA Medical Center, Philadelphia, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸University of Pennsylvania, Philadelphia, PA, ⁹Washington VA Medical Center, Washington, District of Columbia, ¹⁰University of Delaware, Newark, DE, ¹¹Boston University School of Medicine, Boston, MA, ¹²University of Pennsylvania, Philadelphia
Background/Purpose: Intra-articular (IA) corticosteroid injections are commonly utilized for pain management in knee osteoarthritis (KOA). However, clinical characteristics associated with a greater benefit from corticosteroid…
Abstract Number: 1739 • ACR Convergence 2025
Acute Transcriptomic Response of Synovium and Dorsal Root Ganglia to Joint Injury
Michael Newton¹, Lai Wang², Anne-Marie Malfait³, Rachel Miller² and Tristan Maerz⁴, ¹University of Michigan, South Lyon, MI, ²Rush University Medical Center, Chicago, IL, ³Rush University, Oak Park, IL, ⁴University of Michigan, Ann Arbor, MI
Background/Purpose: In arthritic synovium, emerging clinical evidence suggests crosstalk between synovial cells and dorsal root ganglion (DRG) neurons drives nerve sprouting and pain sensitization [Bai+…
Abstract Number: 1256 • ACR Convergence 2025
Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Shannon Teaw¹, Jessica Link-Malcolm², Michelle Ghebranious Farag³, Dorothy Patterson², Jenny Foster⁴, Sofia Bereket², Urooj Wahid², Puneet Bajaj², Elizabeth Solow², Jennifer Barton⁵ and Una Makris⁶, ¹UT Southwestern Medical School, Dallas, TX, ²UT Southwestern Medical Center, Dallas, TX, ³McGovern Medical School at UT Houston, Houston, TX, ⁴UT Southwestern Medical Center, Dallas, ⁵VA Portland Health Care System/OHSU, Portland, OR, ⁶UT Southwestern Medical Center and Dallas VA, Dallas, TX
Background/Purpose: Patients with rheumatic diseases (RD) often experience chronic pain, along with comorbid depression and anxiety, which can be addressed using behavioral health (BH) interventions…
Abstract Number: 1231 • ACR Convergence 2025
TNX-102 SL, Cyclobenzaprine HCl Sublingual Tablets, Demonstrates Pain Reduction and Favorable Tolerability in Patients with Fibromyalgia
Gregory Sullivan¹, Errol Gould², Mary Kelley¹, Jean Engels¹ and Seth Lederman³, ¹Tonix Pharmaceuticals, Inc., Chatham, NJ, ²Tonix Pharmaceutical, Inc., Henderson, NV, ³Tonix Pharmaceuticals, Inc., Austin, TX
Background/Purpose: FDA-approved treatments for fibromyalgia (FM) have historically been limited by intolerable side effects that often lead to poor adherence. TNX-102 SL, a sublingual formulation…
Abstract Number: 0815 • ACR Convergence 2025
Neuropathic-like Pain Characteristics Predict Worse Pain Outcomes in Early Rheumatoid Arthritis: a Prospective Cohort Study with Embedded Neuroimaging Evaluation
Eoin Kelleher¹, Amanda Wall¹, Isabelle Brennan², Robert Murphy¹, Antonella Delmis¹, John Davis³, Vishvarani Wanigasekera⁴, Irene Tracey¹ and Anushka Irani⁵, ¹University of Oxford, Oxford, United Kingdom, ²University of Cambridge, Cambridge, United Kingdom, ³Mayo Clinic, Rochester, MN, ⁴University of Oxford, Oxford, ⁵Mayo Clinic, Jacksonville, FL
Background/Purpose: Despite effective control of inflammation in rheumatoid arthritis (RA), persistent and severe pain remains a clinical challenge. Dysregulated pain processing in the central nervous…
Abstract Number: 0326 • ACR Convergence 2025
Gender Disparities in Clinical Outcomes Among Older Adults with Knee Osteoarthritis: A Retrospective Cohort Study
Kinga Grzybowski¹, Ahmer Khan², Samuel Bonomo³ and Arthur Lau⁴, ¹Jefferson Einstein Montgomery Hospital, Maspeth, NY, ²Jefferson Einstein Philadelphia Hospital, Philadelphia, ³Jefferson Einstein Montgomery Hospital, East Norriton, PA, ⁴Jefferson Einstein Hospital, Maple Glen, PA
Background/Purpose: Osteoarthritis (OA) is the most common type of arthritis which classically affects multiple joints, mainly the knees. About 595 million people worldwide suffer from…
Abstract Number: 2096 • ACR Convergence 2025
Gamification and Social Incentivization to Promote Physical Activity in Adults with Knee Osteoarthritis: Results from a Multi-Site Randomized Trial
Kimberly Hayes¹, Bryant England², Katherine Wysham³, Mercedes Quinones⁴, Marianna Olave⁵, Sarah Wetzel⁶, Hannah Brubeck⁷, Rachel Gillcrist⁸, Criswell Lavery⁹, Natalie Keller¹⁰, Bibiana Ateh¹¹, Bridget Kramer², Rui Xiao⁹, Kaitian Jin⁹, Alexis Ogdie¹², Daniel K. White¹³, Tuhina Neogi¹⁴, Carla Scanzello⁹ and Joshua Baker⁹, ¹Teachers College, Columbia University, Philadelphia, PA, ²University of Nebraska Medical Center, Omaha, NE, ³VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁴Washington DC VA Medical Center, Bethesda, MD, ⁵Brown University, Philadelphia, PA, ⁶Drexel University, Pittsburgh, PA, ⁷VA Puget Sound Health Care System, Seattle, WA, ⁸Dartmouth College, Lebanon, NH, ⁹University of Pennsylvania, Philadelphia, PA, ¹⁰University of Oklahoma, Philadelphia, PA, ¹¹Washington VA Medical Center, Washington, District of Columbia, ¹²Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Wilmington, DE, ¹³University of Delaware, Newark, DE, ¹⁴Boston University School of Medicine, Boston, MA
Background/Purpose: Promotion of physical activity is important in the management of knee osteoarthritis (KOA), though effective strategies for behavioral change to promote exercise are lacking.…
Abstract Number: 1737 • ACR Convergence 2025
CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
Luigino Giancotti, Tiziana Piepoli, Roberto Artusi, Matteo Ghirri, Michela Visintin, Gianfranco Caselli and Lucio Rovati, Rottapharm Biotech, Monza, Italy
Background/Purpose: The inflammatory osteoarthritis (OA) phenotype is characterized by the presence of synovial membrane inflammation, pain and pathological changes in joint structure leading to rapid…
Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Nisha Sapkota¹, Chana Birnbaum², Henna Levitansky², Yevheniia Andriushchenko², Saadia Malik², Melissa Andrade², Sarang Choi² and Sima Terebelo², ¹Interfaith Medical Center, One Broolyn Health, Brooklyn, NY, ²Brookdale Hospital Medical Center, One Brooklyn Health, Brooklyn
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…

1
2
3
…
44
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].